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Carcinogenesis is a multistage process with sequences of
genetic events that govern the phenotypic expression of a se-
ries of transformation steps that lead to the development of
metastatic cancer. To better understand the mechanisms in-
volved in human bronchial carcinogenesis induced by a par-
ticles from radon, we have developed a model of neoplastic
transformation based on human papillomavirus-immortalized
human bronchial epithelial (BEP2D) cells. Cells exposed to a
particles become tumorigenic after progressing through a se-
ries of sequential stages including altered growth pattern, re-
sistance to serum-induced terminal differentiation, agar-pos-
itive growth, tumorigenicity, and metastasis, with each step
representing a necessary yet insufﬁcient step toward the later,
more malignant phase. Cell fusion studies indicated that the
radiation-induced tumorigenic phenotype in BEP2D cells can
be completely suppressed by fusion with nontumorigenic
BEP2D cells. Several cellular differentiation and growth reg-
ulation genes such as DCC (deleted in colorectal cancer),
CDKN1A (also known as p21C1P1) and the gene that encodes
DNA-PK were frequently found to be modulated in tumori-
genic BEP2D cells and may be related to the process of
carcinogenesis. q 2001 by Radiation Research Society
INTRODUCTION
Although radiation is a well-established human carcino-
gen and induces cancers in tissues of diverse histological
origin, the mechanism(s) of radiation carcinogenesis is
largely unknown. The carcinogenic risk for human epithe-
lial cells after exposure to high-LET radiation has been es-
timated to be in the range of 10–12 per cell per gray based
on breast cancer incidence among Japanese A-bomb sur-
vivors (1), an incidence that is too low to be reproduced in
any laboratory setting. To better understand the genotypic
and phenotypic changes associated with radon-induced lung
1 Author to whom correspondence should be addressed at Center for
Radiological Research, Columbia University, VC11-218, 630 West 168th
Street, New York, NY 10032.
cancer in humans, it would be ideal to use human bronchial
cells to assess the various stages of transformation that lead
to malignancies. However, no primary human cell model is
currently available for this area of study because such cells
have proven to be refractory to malignant transformation
in vitro (2). One of the main reasons for this very low
frequency (10–6 to 10–9) is that human cells rarely undergo
spontaneous immortalization (3, 4), which is an essential
step for in vitro neoplastic transformation (5, 6). We have
previously shown that human papillomavirus-immortalized
human bronchial epithelial (BEP2D) cells can be malig-
nantly transformed by a single 30-cGy dose of high-LET
a particles at a frequency estimated to be ;4 3 10–7 after
successive cultivation for 3 to 4 months postirradiation (7,
8). The immortalization step therefore increases the trans-
formation of primary human epithelial cells by a million-
fold. Although the incidence is still a factor of 103–104
lower than those obtained using established rodent cell
models such as C3H 10T½ and NIH 3T3 cells, the use of
immortalized human epithelial cells nevertheless makes it
technically feasible to investigate the later stage of the pro-
cess of neoplastic transformation.
A HUMAN BRONCHIAL CELL MODEL
BEP2D cells were initiated by lipofectin transfection of cloned full-
length HPV-18 into normal bronchial epithelial cells obtained as an out-
growth of a bronchial explant (9). These cells are near diploid and are
relatively stable genotypically over many passages (7, 10). Furthermore,
they are anchorage-dependent and nontumorigenic in nude mice (1, 7, 8).
The observation that BEP2D cells are nontumorigenic even in late pas-
sages suggests that abnormal TP53 and RB functions are not sufﬁcient
criteria for development of tumors and that additional genetic changes
are needed. Transformed BEP2D cells progress through sequential stages
including altered growth kinetics and anchorage-independent growth be-
fore becoming tumorigenic and producing progressively growing subcu-
taneous tumors upon inoculation into athymic nude mice. A few of these
tumors also form metastatic colonies in lung and liver (11). It should be
pointed out that, while the majority of agar-positive BEP2D clones were
nontumorigenic, they all demonstrated the propensity to resist serum-
induced terminal differentiation. In contrast, the majority of tumorigenic
cell lines were agar-positive, suggesting that anchorage-independent
growth is often a necessary but insufﬁcient criterion for tumorigenicity.
Cytogenetic and restriction fragment length polymorphism analysis in-
dicated that many of the radiation-induced transformants had lost various
chromosomal fragments including regions containing putative tumor sup-231 RADIATION-INDUCED NEOPLASTIC TRANSFORMATION
TABLE 1
Changes Associated with Radiation-Induced
Tumorigenicity in BEP2D Cells
No mutation in any of the RAS oncogenes (7)
Absence of microsatellite mutator phenotype (15)
Loss of heterozygosity in polymorphic markers on chromosomes 8 and
14 (10)
Loss of chromosome Y (10)
Overexpression of cyclin D1 (8)
Expression of mutant TP53 with mutations in the TP53 gene (exons 5,
6 and 8) only in secondary and metastatic tumors (11)
Telomerase activity was highest among the metastatic tumors (16)
Contain phosphorylated RB proteins (8)
Down-regulation of the cyclin-dependent kinase inhibitor CDKN1A
FIG. 1. Cell fusion approach for examination of the role of suppressor
functions among tumorigenic BEP2D cells induced by a particles. The
number of animals bearing tumors/the total number of animals injected
for each group is shown.
pressor genes such as those located on chromosomes 8 and 14 (10). It is
clear from these studies that BEP2D cells exposed to a-particle radiation
from radon undergo gradual, sequential changes of altered growth and
anchorage-independent growth before becoming tumorigenic in nude
mice. In addition, each preceding stage represents a necessary yet insuf-
ﬁcient step toward the later, more malignant phase (8, 12).
TUMORIGENICITY IS A RECESSIVE PHENOTYPE
Table 1 lists all the currently known cytogenetic and mo-
lecular alterations associated with the tumorigenic pheno-
type in BEP2D cells induced by high-LET a particles. It is
likely that multiple pathways are involved in the process of
neoplastic transformation. The fact that high-LET radiation
induces predominately multilocus deletions (13, 14) pro-
vides a mechanism for the potential loss of suppressor func-
tions. To determine whether tumorigenicity of BEP2D cells
behaves as a dominant or recessive trait, we carried out cell
fusion studies as shown in Fig. 1. Tumorigenic BEP2D cells
induced by a single 60-cGy dose of a particles were fused
with control cells using polyethylene glycol. Brieﬂy, 5 3
106 tumorigenic BEP2D cells infected with a pRC/CMV
expression vector containing a neo gene were fused with
an equal number of control BEP2D cells containing a p-
Babe plasmid which is resistant to puromycin using 1 ml
of prewarmed 50% PEG 1500. The PEG was added drop-
wise over 1 min to initiate the cell fusion process and was
followed by the addition of 20 ml of culture medium over
6 min with constant agitation. The resulting fusion cells
were then selected by incubation in medium containing
both G418 and puromycin over a 12-day period. The fusion
cells were expanded in culture and reinoculated into nude
mice for expression of the tumorigenic phenotype. Controls
involving the fusion of tumor–tumor and control–control
cells were conducted similarly. Results of these fusion ex-
periments demonstrated that the radiation-induced tumori-
genic phenotype in BEP2D cells could be completely sup-
pressed by fusion with nontumorigenic BEP2D cells. Fur-
thermore, concurrent fusion of tumor cells with tumor cells
resulted in tumorigenic hybrids, whereas fusion of wild-
type BEP2D cells resulted in nontumorigenic hybrid clones.
These data indicate that nontumorigenic BEP2D cells com-
plement the loss of putative suppressor elements among
tumorigenic cells and suggest loss of suppressor gene(s) as
a likely mechanism of radiation carcinogenesis.
SEARCHING FOR TRANSFORMING GENES
The differential expression of known genes between tu-
morigenic BEP2D cells induced by a particles and control
BEP2D cells was compared using a cDNA expression array
(Clontech, Palo Alto, CA) as shown in Fig. 2. Brieﬂy, total
RNA from both tumorigenic and control BEP2D cells was
isolated using Trizol Reagent (Gibco, Grand Island, NY).
Then the isolate was treated with DNase I to remove any
contaminating DNA from the RNA preparation as de-
scribed (1, 8). PolyA1 RNA was then isolated, and 32P-
labeled complex cDNA probes were generated by reverse
transcription in the presence of 32P-labeled dATP. The
cDNA probes were then hybridized to the nylon mem-
branes and the hybridization patterns were analyzed by au-
toradiography. The intensity of the signal, which corre-
sponded to the expression levels of the individual genes,
was quantiﬁed using phosphorimaging analysis. Overall,
mRNA was prepared and analyzed at least three times from
each tumor and control cell line examined.
As shown in Fig. 2, the Clontech cDNA expression array
contains six quadrants which covers different categories of
genes, including oncogenes, tumor suppressor genes, intra-
cellular signal transduction modulators, DNA synthesis and
repair genes, transcription factors, and receptor and growth
factor genes. Each cDNA of the 588 preset genes was spot-
ted in duplicate on the membranes. The hybridization sig-
nals appearing at the bottom of the array were various
housekeeping genes intended to be used as positive con-
trols. A series of 10 genes were identiﬁed to be differen-
tially expressed between the two cell lines examined in-
cluding the genes which code for the M-phase inducer pro-232 ZHAO ET AL.
FIG. 2. Differential gene expression in a representative tumorigenic BEP2D cell induced by a single 60-cGy dose of a particles (T5L2P, right panel)
relative to control BEP2D cells (left panel). The labeled cDNAs were hybridized to the array overnight at 658C. The image was captured on X-ray
ﬁlm by exposure for 2 days at 2808C. Arrows indicate the location of the cDNA spots on the membrane for (1) CDC5B and (2) HSP27.
TABLE 2
List of Differentially Expressed Genes between
Tumorigenic and Control BEP2D Cells Based on
mRNA Values
Gene Expression level
DCC tumor suppressor
DNA-dependent protein kinase
Heat-shock protein 27
Cytokeratin 14
Alpha-catenin
CDKN1A
Glutathione-S-transferase
CDC25B (M-phase inducer)
MYC
Fibronectin
¯ 2.1 6 0.2
¯ 2.2 6 0.5
¯ 4.9 6 2.3
¯ 5.0 6 0.8
¯ 2.2 6 0.5
¯ 4.4 6 2.1
­ 2.1 6 0.4
­ 3.3 6 1.2
No change
No change
FIG. 3. Northern blot analysis showing the relative levels of the
mRNA of CDKN1A (p21cip1) in control BEP2D cells (lane 1), irradiated
BEP2D cells 1 week postirradiation (lane 2), irradiated cells just before
inoculation into nude mice (lane 3), and ﬁve representative tumor cell
lines (lanes 4 through 8). The RNA blot was hybridized to 32P-labeled
human CDKN1A probe. The relative abundance of RNA per lane was
judged to be similar based on the b-actin level.
tein, CDC25B (number 1, arrow in upper left quadrant) and
heat-shock protein 27 (number 2, arrow in upper middle
quadrant, Fig. 2).
Since the incidence of false positives among cDNA ex-
pression analyses can be as high as 15–20%, it is essential
to double-check the message level using Northern blotting.
Figure 3 shows the expression level of CDKN1A (also
known as p21CIP1) among control and tumorigenic BEP2D
cells induced by a single 60-cGy dose of a particles. In
control (lane 1) and irradiated BEP2D cells 1 week post-
irradiation (lane 2), the expression level of CDKN1A was
about twofold higher than that in the irradiated population
prior to their injection into nude mice (lane 3). Among
tumorigenic BEP2D cells, the average expression level of
CDKN1A was about fourfold lower than that of the control
BEP2D cells (lanes 4 through 8). It should be noted that
equivalent quantities of mRNA based on the expression
level of control b-actin were loaded into each lane. Table
2 lists the differentially expressed genes and their relative
expression levels pooled from 5–8 tumorigenic BEP2D cell
lines induced by a particles. Expression levels of the in-
dividual genes were compared relative to the level of the
b-actin gene from the same membrane. Among the 10
genes initially identiﬁed as differentially expressed, MYC
and ﬁbronectin could not be conﬁrmed when subsequently
analyzed by Northern blotting. Several cell growth and dif-
ferentiation genes were found to be down-regulated in the
tumorigenic BEP2D cells relative to their corresponding
controls. These included the DCC tumor suppressor gene,
the DNA-dependent protein kinase gene (PRKDC), the dif-
ferentiation marker cytokeratin CK14, and the cell cycle
modulator CDKN1A gene.
CDKN1A is a cyclin-dependent kinase inhibitor that can
effectively inhibit CDK2, CDK4 and CDK6 and is capable
of inducing cell cycle arrest in G1 phase when it is over-
expressed. Although CDKN1A is induced by TP53 in re-
sponse to radiation, CDKN1A can be expressed at high
levels in TP53-negative cells, indicating the existence of
TP53-independent mechanisms to regulate CDKN1A ex-
pression (17). There is evidence that CDKN1A may be
involved in the G2-phase checkpoint regulation in addition
to exerting negative control of the G1/S-phase transition
(18). The down-regulation of CDKN1A has been shown to
increase CDC2 and CDK2 activity and promote cell cycle
progression and cell proliferation (19). Reduced levels of
CDKN1A protein have been reported in many human can-233 RADIATION-INDUCED NEOPLASTIC TRANSFORMATION
cers and may contribute to malignant progression (20). On
the other hand, overexpression of CDKN1A has been
shown to inhibit the growth of several tumor cell lines (21).
In the present study, the level of expression of CDKN1A
mRNA was found to be down-regulated twofold in radia-
tion-treated late-passage cells and fourfold in tumorigenic
cells even though TP53 was already inactivated by the pres-
ence of E6 oncoprotein in BEP2D cells. These data suggest
the presence of a TP53-independent regulatory pathway of
CDKN1A expression that is likely to play an important role
in malignant progression induced by radiation.
DCC (deleted in colorectal cancer) is a candidate tumor
suppressor gene that is postulated to function as a trans-
membrane receptor that belongs to the immunoglobulin su-
perfamily (22). Frequent allelic deletions and loss of its
expression and somatic mutations have been seen not only
in colorectal cancer but also in a number of other cancers
as well (23). Inactivation of the DCC gene may enhance
the ability of tumor cells to invade and metastasize (24).
Some of the strongest evidence supporting a role for DCC
as a tumor suppressor gene comes from studies showing a
suppression of tumorigenicity in nude mice by expression
of full-length, but not truncated, DCC in nitrosomethylurea
(NMU)-transformed keratinocytes lacking DCC expression
(25). When DCC cDNA is transfected into tumor cells, apo-
ptosis and G2/M-phase cell cycle arrest are induced by cas-
pase-3 activation and inhibition of CDK1, suggesting a pos-
sible mechanism by which DCC suppresses tumorigenesis
(26).
The CDC25 family of mammalian phosphatases includes
three homologues, CDC25A, CDC25B and CDC25C,
which can activate cyclin-dependent kinases by removing
inhibitory phosphates from tyrosine and threonine residues.
The CDC25 functions at the G1/S-phase and G2/M-phase
borders (27). The overexpression of CDC25B was ob-
served in many breast, head and lung cancers (28). The
CDC25B cooperates with HRAS or loss of RB1 in onco-
genic transformation, and high expression of CDC25B in a
portion of primary breast cancers correlates with less fa-
vorable prognosis and poor survival (29). Reduced
CDC25B mRNA level and deregulated protein expression
by antisense oligonucleotides result in S-phase delay and
antiproliferative effects in synchronized HeLa cells (30).
This evidence indicates that CDC25B possesses oncogenic
properties and is consistent with our observation that
CDC25B was up-regulated threefold in tumor cells, sug-
gesting that an overexpression of CDC25B may play an
important role in radiation carcinogenesis.
Identiﬁcation of the stepwise molecular alterations in car-
cinogenesis is one of the major goals in cancer research.
The cDNA array provides a useful method to screen dif-
ferentially expressed genes between control and tumorigen-
ic BEP2D cells. Although our present study identiﬁed a
number of differentially expressed genes in tumorigenic
and control BEP2D cells, the nature of the interaction of
these genes in modulating radiation-induced tumorigenesis
is not yet clear. It is likely that a concerted effort by many
genes rather than loss of a single suppressor function is
critical for the tumorigenic phenotype. For example, a re-
duced expression level of PRKDC may contribute to ge-
netic instability of transformed BEP2D cells (31). Subse-
quent down-regulation of the E-cadherin-catenin complex
may enhance invasiveness of transformed cells (32). To-
gether with the cytokeratin 14 gene, whose expression is
down-regulated by ﬁvefold in tumorigenic cells, these al-
tered gene expressions may serve as a useful biomarker for
the transformed phenotype of BEP2D cells. Understanding
the genes and their products that regulate tumor progression
and invasiveness are of critical importance not only for a
better understanding of the mechanism of radiation carci-
nogenesis but also as an aid in the eventual design of novel
prognostic and therapeutic approaches.
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